OcuTerra Therapeutics

0 followers


OcuTerra is developing a novel eye drop, OTT166, designed to treat diabetic eye disease. This first-in-class, highly disruptive treatment has the potential to treat diabetic eye disease earlier and more efficiently, with established clinical data showing safety and demonstrating biological activity

Industries

Headquarters

Stage

Employees

Links

Org chart

David J. Tanzer
Chief Medical Officer
Susannah Sinozich
Senior Clinical Program Director